Figure 1




Screening
Double-blind placebo-controlled
Open-label
Up to 2 weeks
24 weeks
80 weeks
Adalimumab 40 mg eow (N=38)
Patients (N=82)
Primary analysis
Statistical analysis
Adalimumab 40 mg eow
Placebo (N=44)
Week
0
12
24
104
Early escape option at Weeks 12, 16, 20

Figure 2


Change in CTX-II Concentrations at Weeks 12 and 24†



†LOCF Adjusted means *** Statistically significant at the p=0.001 level, adalimumab vs. placebo


Figure 3

Change in MMP3 Concentrations at Weeks 12 and 24†



†LOCF Adjusted means *** Statistically significant at the p=0.001 level, adalimumab vs. placebo

Figure 4



† LOCF ***Statistically significant at p=0.001 level. p-value for difference between therapies from ANCOVA